This cardiac device maker focused on atrial fibrillation saw a notable insider sale following a year of flat share performance.Sven Wehrwein, a member of the Board of Directors at AtriCure (ATRC +0.25%), exercised 10,000 non-qualified stock options and immediately sold the underlying shares in derivative transactions on November 24 and November 25, 2025, as reported in the SEC Form 4 filing.Transaction summaryMetricValueShares sold10,000Transaction value~$376,600Post-transaction shares34,374Post-transaction ...